Patent · US Expired

Drug for the treatment of cancer

US6156725A · kind A · utility

6Cited by
2References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 8, 1996
Grant dateDec 5, 2000
Priority date
Expiry dateOct 8, 2016

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/10
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A pharmaceutical composition useful for killing or inhibiting multiplication of cancer cells. It is expected that the pharmaceutical composition will be useful in preventing, inhibiting, or modulating the hypersecretion of VIP, somatostatin, bombesin, Substance P, or a combination of VIP, somatostatin, bombesin, or Substance P. The composition may suitably comprise, consist of, or consist essentially of a therapeutically effective combination of peptide analogs of somatostatin, VIP, bombesin, and Substance P. Also provided is a method of treatment for humans or other animals suffering from cancer, the method comprising administering a therapeutically effective dose of the pharmaceutical composition so as to kill or inhibit the multiplication of cancer cells. The method of treatment may be particularly useful in the treatment of cancers of the colon and rectum. Also provided is a method of treatment for humans or animals having hypersecretion or modulation of VIP, somatostatin, bombesin, Substance P, or a combination of VIP, somatostatin, bombesin, or Substance P.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.